The end of turmoil

Three major developments in Brazil suggest the country is entering an exciting era for IP owners. Gabriel Francisco Leonardos and Pedro Vilhena of Kasznar Leonardos report.
Brazil is well known for its football players, beaches and caipirinhas, but IP practitioners everywhere have grown used to linking Brazil to a far less flattering reality: the gargantuan backlog of patent and trademark applications.
On average, for the last 15 years the Brazilian Patent and Trademark  Office (lNPI) has been taking between two and five years to examine a trademark application and from seven to 14 years to exan1ine a patent filing. This is, by far, the largest examination time among comparable economies. It is also the source of many problems for IP rights holders in the country.
The current situation of the INPI reflects the difficulties faced by the public sector in Brazil. In 2014, following a decade of hope and growth, the country plunged into an unprecedented economic and political crisis that affects both national and local governments, not to mention the manufacturing sector.
President Michel Temer took office after the impeachment of Dilma Rousseff, affirming the need for reforms but clarifying that the moment required austerity. In other words, government bodies should cut their budgets.
Less than a year later, the government still claims that it needs to cut all excesses and refrain from increasing governmental help to agencies, bodies and institutions. The cuts include reduced Three major developments in Brazil suggest the country is entering an exciting era for IP owners. Gabriel Francisco Leonardos and Pedro Vilhena of Kasznar Leonardos report. funding of public universities, scholarships and programmes.
Nevertheless, . the INPI remains a notable exception. Not only did the general cuts not hit the agency budget, but also there has been some indication that the government may increase the INPis allocated resources soon. The government's economic development team seems to acknowledge the importance of IP rights in attracting foreign investments and boosting local innovation.
While political turmoil persists and lacklustre economic figures reveal a fading, but persistent, crisis, the news is outstanding in the IP field Three substantial issues haunting our country in recent years were tackled on April 12, which was an unusual day for the Brazilian IP system.
Quicker examination for pharma patents
Back in 1999, a statutory change gave the Brazilian health regulatory agency ANVlSA the power to reject pharmaceutical patent applications. In fact, the law set forth that ANVISA must give its prior approval to pharmaceutical patent applications. It was the beginning of a feud between the two agencies whose effects fell upon applicants. The criteria ANVISA could assess in connection to its approval of a given application were never clear. The health regulatory agency claimed it could  examine not only public health and safety aspects, but also all patentability requirements, especially if the drugs were to be purchased by the Brazilian public health system. The INPI, on the other hand, claimed that only it should analyse patentability requirements and held that ANVISAS examination should be limited to health and safety aspects.
The feud materialised in several lawsuits, with the courts consistently rejecting ANVISA's far-reaching interpretation of its own authority and deciding that patentability criteria (namely novelty, non-obviousness, industrial use and sufficiency of disclosure) could be examined only
by the INPI.
Now, it seems that there shall be no more separate examination of patentability requirements by the INPI and ANVlSA, as the agencies entered into a memorandum of understanding (MoU), executed in a ceremony in Brasilia and chaired by Temer. It was agreed that only the INPI is entitled to examine patentability requirements even if, under the 1999 statute, ANVlSA is still empowered to examine patent applications in relation to health and safety concerns.
While this is not a complete solution for a complicated problem, the MoU may decrease the
prosecution period of a pharmaceutical patent application (currently around 12 years) and reduce the number of litigation procedures in connection with pharmaceutical patents.
New examiners
Another announcement, by the INPI's president, reinforced the perspective of a substantial decrease in the agency's examination time. On April 6. 70 new patent and trademark examiners started work This group had been approved in exams done in 2014, but their hiring had been delayed by budgetary concerns. The federal government has authorised that they be admitted.
This is the second hiring plan in recent years. Last year, 140 new examiners were engaged. Altogether, the increase of 210 examiners in two years represents a rise of approximately 25%in the agencys personnel. Upon completion of training sessions during an adaptation period,
the new examiners are expected to contribute to an increase of the agencys productivity, speeding up examination and reducing the backlog of applications.
It is also important to mention that INPI has not looked for shortcuts. Until now, there have been no automatic rulings on pending applications (either accepting or rejecting, thus transferring the problem to appellate bodies and courts) or a term for applicants to file a confirmation of interest (with automatic rejection of the remaining cases). The INPI has been avoiding simplistic solutions towards drastically reducing the backlog in the short term, a testament to the seriousness of the Brazilian IP system.
Less governmental interference
The final announcement on April 12 concerned the registration of technology transfer and
IF-related agreements by the INPI. The mandatory registration of such agreements has been labelled extremely invasive, often compelling private parties to amend conditions that had been freely agreed upon in order to secure approval.
Whereas registration was necessary for tax deduction of payments and for remittance of royalties abroad, most companies simply agreed to the conditions imposed by the agency. In some cases, however, contracting parties challenged the conditions imposed by the INPI in lawsuits, with inconsistent results. The tension between favourable and negative decisions in the case law became history with the enactment of Normative Instruction 70 of 2017, under which the INPI replaces the examination of the merits of each agreement by a mere verification of the applicable formalities.
Henceforth, the INPI will no longer examine the payment clause of the agreements and will approve the registration of them. A general disclaimer will be included in every certificate of registration stating: “the INPI has not examined the agreement under the statutory rules pertaining to tax and foreign exchange control law”.
The new procedure entails a higher responsibility for the parties, since royalties may be remitted abroad and tax deducted more easily, but approval by INPI will no longer serve as a defence in tax procedures.
Turmoil is gradually fading, leaving a place for a new cycle of economic growth and social stability in Brazil. Among the many ongoing reforms, it is reassuring to see that the INPI is finally able to reclaim a prominent place in the country’s political landscape.
Many young IP practitioners in Brazil had never seen the INPI under the spotlight, reinforcing the symbolism of having Brazil’s president chairing an event with the INPI.
Brazil may be facing the beginning of a new trend in our IP system, with the possible reduction in prosecution delay of applications and policies that are more predictable and business-friendly. For the first time in several decades, IP and the INPI have become a priority of the federal government, showing that a political environment more friendly towards innovation is finally arriving in Brazil.
This article originally appeared on WIPR ANNUAL 2017 .

Last related news

September 14, 2023

On the cusp of change: patent landscape overhaul is good news for healthcare innovation in Brazil

Check out the article “On the cusp of change: patent landscape overhaul is good news for healthcare innovation in Brasil”,  published on IAM Media, authored by On the cusp of change: patent landscape overhaul is good news for healthcare innovation in Brazil

Ler notícia

August 4, 2023

Cannabis and IP: Nurturing innovation in Brazil’s Life Sciences industry

Check out the article “Cannabis and IP: Nurturing innovation in Brazil’s life sciences industry”, authored by Priscila Kashiwabara and Luan Scalzitti and Cannabis and IP: Nurturing innovation in Brazil’s Life Sciences industry

Ler notícia

June 16, 2023

They aimed at the Louboutin sole, but hit the Osklen sneaker!

Jokes aside in the title, despite having discussed for years the possibility of registering or not the famous red sole of Louboutin They aimed at the Louboutin sole, but hit the Osklen sneaker!

Ler notícia